Conversely, the incidence of anemia, decreased neutrophils count, decreased platelets, fatigue, nausea, increased ALT/AST, pleural effusion, gastroenteritis, and rash was higher in the Pembrolizumab group compared to the Sintilimab group. This evidence concerns the gene GPT and gastroenteritis.